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Introduction. Clostridium diﬃcile-associated disease (CDAD) is treated using antibiotics, which often leads to the emergence of
antibiotic-resistant bacteria such as vancomycin-resistant enterococci (VRE). This study estimated the impact of a non antibiotic
treatment for CDAD on VRE prevalence. Methods. A previously published model describing the impact of in-hospital antibiotic
useonVREprevalencewasadaptedtoincludeCDADtreatment.SimulationscomparedtheprevalenceofVREwhennonantibiotic
versusantibiotictherapywasused.Results.Nonantibiotictreatmentin50%ofCDADpatientsresultedinan18%relativereduction
in the prevalence of VRE colonization compared with antibiotic use only. Sensitivity analysis found the model to be most sensitive
to rates of antibiotic initiation and discontinuation, prevalence of VRE in admitted patients, length of stay of colonized patients,
probability of CDAD acquisition, and hand-washing compliance. Conclusion. Nonantibiotic treatment of patients hospitalized
with CDAD may signiﬁcantly reduce the incidence of VRE colonization.
1.Introduction
The bacterium Clostridium diﬃcile is the most common
cause of hospital-acquired diarrhea, accounting for up to
25% of all cases of antibiotic-associated diarrhea [1, 2]. Rates
of colonization of inpatients with C. diﬃcile may be as high
as 50% for patients hospitalized for more than four weeks
[3]. The incidence of C. diﬃcile-associated disease (CDAD)
has been growing on the basis of data from the National
Nosocomial Infections Surveillance system [3]. Importantly,
outbreaks of severe CDAD cases have occurred in several
hospitals because of the emergence of a new C. diﬃcile strain
with increased virulence and antibiotic resistance [4, 5]. This
more virulent bacterial strain results in more admissions to
the intensive care unit, colectomies, and death than other
strains [4, 5]. A recent study reported that in the United
States,theincidenceofadultCDADhospitalizationsdoubled
from 5.5 cases per 10,000 population in 2000 to 11.2 per
10,000 cases in 2005, and the age-adjusted CDAD-related
case-fatality rate rose from 1.2% in 2000 to 2.2% in 2004 [6].
Current treatment of CDAD involves antibiotic ther-
apy with either metronidazole or vancomycin. However,
there has been a growing interest in the development of
nonantibiotic therapies for CDAD and other nosocomial
infections in order to reduce antibiotic use in hospitals,
where the goal is to limit the emergence and spread of
antibiotic-resistant bacteria such as vancomycin-resistant
enterococci (VRE) [7]. The use of such antibiotics can
eradicate antibiotic-susceptible bacterial strains in the gas-
trointestinal ﬂora, thereby allowing the overgrowth of
subpopulations of antibiotic-resistant bacteria [8, 9]. In
the case of C. diﬃcile treatment, both metronidazole and
vancomycin are associated with the promotion of VRE.
This overgrowth is evidenced by the cocolonization of C.2 Computational and Mathematical Methods in Medicine
diﬃcile and VRE that occurs in 20% to 34% of patients,
which may reﬂect C. diﬃcile-directed antibiotic exposure
as well as other common risk factors for these pathogens
[10–12].
It has been suggested that nonantibiotic treatment of
CDAD may oﬀer an opportunity to reduce antibiotic use in
hospitals and could ultimately decrease the prevalence and
burden of VRE. For example, although ultimately unsuccess-
ful, the enterotoxin-binding polymer tolevamer (Genzyme,
Inc.) was investigated for the treatment of CDAD in 2008
[13, 14]. More recently, a number of small studies have
reported on the successful use of fecal donor instillation
therapy (FDIT) for the treatment of patients with CDAD
[15–17]. Used for decades in some hospitals, only recently
has the eﬀectiveness of this therapy been documented in
the literature. In a retrospective study of 40 patients with
recurrent CDAD, 83% of patients were successfully treated
with FDIT, having met the study’s endpoint of no further
hospital contact due to CDAD symptoms within 80 days
of therapy. While in the study’s protocol patients were
treated with metronidazole or vancomycin until reduction of
symptoms,allantimicrobialtherapywasdiscontinuedonthe
evening prior to donor stool transplantation [18].
The objective of this study was to estimate the potential
impact of a nonantibiotic treatment for CDAD on the
prevalence of VRE within a hospital setting. A mathematical
model was used to estimate and compare the prevalence
of VRE with current antibiotic therapies for CDAD versus
nonantibiotic therapies such as FDIT.
2. Methods
The current model (Appendix) extends a previously pub-
lished model by D’Agata and colleagues (2005) that
described the impact of antibiotic use on VRE prevalence
within a hospital setting [19]. The model considers the
admission of patients with and without VRE to a hospital
and their consequent risks of CDAD and VRE acquisition.
Since VRE is predominantly spread from patient-to-patient
via the contaminated hands or clothes of health care workers
(HCWs), the complex interactions between patients and
HCWs were also incorporated into the model. The model
describes the transmission dynamics of VRE in a 400-bed
hospital. The original model compartmentalized patients
into those receiving (right side of Figure 1) and not receiving
(left side of Figure 1) antibiotics, and those who were VRE-
colonized (bottom boxes in Figure 1) and those who were
not (top boxes in Figure 1). The original model was then
extended to include CDAD status. Each of the four original
boxes was divided into an outer and inner box, and CDAD
positive (CDAD+) patients were included in the inner boxes
3, 4, 5, and 6. These boxes included CDAD patients who
were not receiving antibiotics and were either uncolonized
(Box 3) or colonized (Box 5) with VRE as well as individuals
who were receiving antibiotics and were either uncolonized
(Box 4) or colonized (Box 6) with VRE.
All model parameter values are provided in Table 1.
Exceptwherenotedbelow,thesamevaluesfromD’Agataand
c o l l e a g u e s ’m o d e lw e r eu s e d .T h e s ev a l u e sw e r eo r i g i n a l l y
obtainedfrompharmacyrecordsandanobservationalHCW
study at Beth Israel Deaconess Medical Center [19]. The
spread of VRE between patients and associated movement
between compartments occurred because of HCWs whose
hands were contaminated with VRE after contact with a col-
onized patient (Figure 2). The interaction between patients
and HCWs included the number of contacts with a patient
during routine patient care and compliance with hand
hygiene (Table 1). The latter was an important inclusion,
since hand hygiene will remove VRE from HCWs’ hands
and thereby prevent transmission of VRE to patients. It was
assumed that patients who were colonized with VRE were on
contact precautions and therefore less likely to contaminate
HCWs. The implementation of these precautions is standard
practice in hospital settings and requires HCWs to don
gloves and gowns prior to entering the room of a VRE-
colonized patient in order to prevent HCW contamination
[20].
The movement between compartments was also inﬂu-
enced by the proportion of patients who were started on
antibiotics or in whom antibiotics were discontinued. It was
assumed that patients receiving antibiotics were more likely
to contaminate an HCW, since studies have documented
that antibiotic exposure results in increased VRE stool
densities and a greater likelihood of skin contamination
(Table 1)[ 9]. Although contamination of HCWs’ clothes
and inanimate surfaces contribute to VRE dissemination,
these factors were omitted in order to simplify the model
[21].
The probability of colonization per contact between
uncolonized CDAD patients on antibiotics and contam-
inated HCW (0.16) was based on an assumption that
contact precautions for CDAD+ patients would decrease the
probability of contamination by 60% compared to patients
without CDAD [22]. These values were obtained from
studies focusing on Acinetobacter spp. The daily probability
of patients on antibiotics to transit to CDAD+ (15/14 =
1.07%) was based on an overall risk of CDAD infection for
antibiotic-treated patients of 15% and an average length of
stay of 14 days, as per the original model [19]. The daily
probability of CDAD resolution of 27.03% = 100 (3 × 9+
10 × 0.1) was based on the assumption that 90% of CDAD
cases resolve within 3 days and 10% require 10 days [23].
The model was run until it reached a steady state, and
the total numbers of patients in each state was compared
in two scenarios: (1) all patients received antibiotics for
treatment of CDAD in hospital and (2) a subgroup of CDAD
patients received a nonantibiotic treatment for CDAD with
equal eﬃcacy to antibiotic therapy. First, to simulate current
care for CDAD with antibiotic therapy and the lack of a
nonantibiotic treatment option, the transition probabilities
for entry into boxes 3 and 5 were set to zero. Second, to
simulate the impact of avoiding antibiotic exposure with the
use of a nonantibiotic therapy for CDAD, 50% of patients
acquiring CDAD were assumed to discontinue antibiotics
a n dm o v et ob o x e s3a n d5 .Computational and Mathematical Methods in Medicine 3
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Figure 1: Schematic diagram of the patient compartments. CDAD = clostridium diﬃcile-associated disease; CDAD+ = clostridium diﬃcile-
associated disease positive; CDAD− = clostridium diﬃcile-associated disease negative; VRE = vancomycin-resistant enterococci; VRE+ =
vancomycin-resistant enterococci colonized; VRE− = vancomycin-resistant enterococci not colonized; AB− = oﬀ antibiotics; AB+ = on
antibiotics; λoﬀ
U− = CDAD−, uncolonized, oﬀ antibiotic: admission rate; γoﬀ
U−= CDAD−, uncolonized, oﬀ antibiotic: average length of stay;
λon
U−= CDAD−, uncolonized, on antibiotic: admission rate; γon
U−= CDAD−, uncolonized, on antibiotic: average length of stay; τ
stop
U− = CDAD−,
uncolonized, on antibiotic: stop antibiotic; τstart
U− = CDAD−, uncolonized, oﬀ antibiotic: start antibiotic; δoﬀ
U+= CDAD+, uncolonized, oﬀ
antibiotic: transit to CDAD−; σ = fraction of AB patients that transit to CDAD+ and stop AB; ωon
U−= CDAD−, uncolonized, on antibiotic:
transit to CDAD+; δon
U+ = CDAD+, uncolonized, on antibiotic: transit to CDAD−; αon
U+= average number of contacts between uncolonized
CDAD− patients on antibiotic and HCW; βon
U+= probability of colonization per contact between uncolonized CDAD+ patient on antibiotic
andcontaminatedHCW;αon
U−=averagenumberofcontactsbetweenuncolonizedCDAD+patientsonantibioticandHCW;βon
U−=probability
ofcolonizationpercontactbetweenuncolonizedCDAD−patientonantibioticandcontaminatedHCW;η =handwashingcompliancefactor
between 0 and 1; δoﬀ
C+= CDAD+, colonized, oﬀ antibiotic: transit to CDAD−; ωon
C−= CDAD−, colonized, on antibiotic: transit to CDAD+; δon
C+
=CDAD+,colonized,onantibiotic:transittoCDAD−;λoﬀ
C−=CDAD−,colonized,oﬀantibiotic:admissionrate;τ
stop
C− =CDAD−,colonized,on
antibiotic: stop antibiotic; λon
C−= CDAD−, colonized, on antibiotic: admission rate; τstart
C− = CDAD−, colonized, oﬀ antibiotic: start antibiotic;
γon
C−= CDAD−, colonized, on antibiotic: average length of stay; γoﬀ
C−= CDAD−, colonized, oﬀ antibiotic: average length of stay.
3.SensitivityAnalyses
Univariate sensitivity analyses were conducted for percent of
CDAD+ patients that stop antibiotics and start a nonantibi-
otic treatment, number of colonized patients admitted per
day, length of stay of colonized patients, percentage of hand-
washing compliance, percentage of uncolonized patients on
antibiotics that become CDAD+, and time to symptoms
resolution of colonized CDAD+ patients on antibiotics.
4. Results
The distributions of patients in each steady state under both
scenariosaresummarizedinT able2.Undertheﬁrstscenario,
where antibiotics were used for all CDAD+ patients (σ =
0.0), of the approximately 400 patients in the steady state,
60 (15.0%) were colonized with VRE, 194 (48.5%) were on
antibiotics, and 6 (1.5%) were CDAD+, all of whom were
on antibiotics (Table 2). Under the second scenario, where
50% of CDAD+ patients discontinued antibiotics in favor
of a nonantibiotic treatment (σ = 0.5), VRE colonization
was reduced. In this scenario, the total number of patients
on antibiotics declined to 185 (46.3%) and the number of
CDAD+ patients receiving antibiotics declined to 3 (0.75%).
The total number of patients who were VRE-colonized at
any given time declined from 60 to 49 (from 15.0% down to
12.25%), an absolute decline of 2.75% and a relative decline
of18%.Assuminga400-bedhospitaland25patientsperbed
a year, this outcome translates into 275 avoided cases of VRE
colonization per year.
Results of the sensitivity analyses are presented in
Figure 2. In all analyses, the nonantibiotic use scenario was
associated with a lower prevalence of VRE colonization. In
the nonantibiotic scenario, the percentage of VRE-colonized4 Computational and Mathematical Methods in Medicine
Table 1: Parameters used in modeling the eﬀect of antibiotic versus nonantibiotic treatment of CDAD on VRE colonization.
Parameter Patients Value
Np number of patients in the hospital 400
ρ ratio of patients to HCW 4
λoﬀ
U− CDAD−, uncolonized, oﬀ antibiotic: admission rate 50.1 per day
γoﬀ
U− CDAD−, uncolonized, oﬀ antibiotic: average length of stay 5 days
λon
U− CDAD−, uncolonized, on antibiotic: admission rate 2.505 per day
γon
U− CDAD−, uncolonized, on antibiotic: average length of stay 14 days
λoﬀ
C− CDAD−, colonized, oﬀ antibiotic: admission rate 0.334 per day
γoﬀ
C− CDAD−, colonized, oﬀ antibiotic: average length of stay 28 days
λon
C− CDAD−, colonized, on antibiotic: admission rate 0.501 per day
γon
C− CDAD−, colonized, on antibiotic: average length of stay 28 days
τ
stop
U− CDAD−, uncolonized, on antibiotic: stop antibiotic 15% per day
τstart
U− CDAD−, uncolonized, oﬀ antibiotic: start antibiotic 15% per day
τ
stop
C− CDAD−, colonized, on antibiotic: stop antibiotic 4% per day
τstart
C− CDAD−, colonized, oﬀ antibiotic: start antibiotic 16% per day
σ fraction of CDAD+, on antibiotic: stop antibiotic 0.5
αon
U+
average number of contacts between uncolonized 8 per day
CDAD− patients on antibiotic and HCW
αon
U−
average number of contacts between uncolonized 8 per day
CDAD+ patients on antibiotic and HCW
βon
U+
probability of colonization per contact between uncolonized 0.024
CDAD+ patient on antibiotic and contaminated HCW
βon
U−
probability of colonization per contact between uncolonized 0.06
CDAD− patient on antibiotic and contaminated HCW
ωon
U− CDAD−, uncolonized, on antibiotic: transit to CDAD+ 1.07% per day
ωon
C− CDAD−, colonized, on antibiotic: transit to CDAD+ 1.07% per day
δon
C+ CDAD+, colonized, on antibiotic: transit to CDAD− 27% per day
δoﬀ
C+ CDAD+, colonized, oﬀ antibiotic: transit to CDAD− 27% per day
δon
U+ CDAD+, uncolonized, on antibiotic: transit to CDAD− 27% per day
δoﬀ
U+ CDAD+, uncolonized, oﬀ antibiotic: transit to CDAD− 27% per day
σ fraction of AB patients that transit to CDAD+ and stop AB 0.0 or 0.5
Parameter Health care workers Value
αC+ average number of contacts between HCW and colonized CDAD+ patients 10 per day
αC− average number of contacts between HCW and colonized CDAD+ patients 10 per day
κon
−
probability of contamination per contact between uncontaminated 0.4
HCW and colonized CDAD− patient on antibiotic
κoﬀ
−
probability of contamination per contact between uncontaminated 0.4
HCW and colonized CDAD− patient oﬀ antibiotic
κon
+
probability of contamination per contact between uncontaminated 0.16
HCW and colonized CDAD+ patient on antibiotic
κoﬀ
+
probability of contamination per contact between uncontaminated 0.16
HCW and colonized CDAD+ patient oﬀ antibiotic
μ average duration of HCW contamination 48 minutes
η hand-washing compliance factor between 0 and 1 0.6
CDAD=clostridiumdiﬃcile-associateddisease;VRE=vancomycin-resistantenterococci;HCW=healthcareworker;CDAD+=clostridiumdiﬃcile-associated
disease positive; CDAD− = clostridium diﬃcile-associated disease negative; AB = antibiotics.
patients decreased notably if the percentage of CDAD+
patients that stop antibiotics and start a nonantibiotic reg-
iment increased (Figure 2(a)), the hand-washing compliance
percentage increased (Figure 2(d)), or the percentage of
uncolonized patients on antibiotics that become CDAD+
increased (Figure 2(e)). With both antibiotic and nonan-
tibiotic therapies, the percentage of VRE-colonized patients
increased notably when the number of colonized patients
admitted per day increased (Figure2(b)) or the length of stay
of colonized patients increased (Figure 2(c)).Computational and Mathematical Methods in Medicine 5
0 2 04 06 08 0 1 0 0
10
11
12
13
14
15
P
a
t
i
e
n
t
s
 
c
o
l
o
n
i
z
e
d
 
(
%
)
CDAD+ patients that stop AB and start non-AB (%)
(a)
P
a
t
i
e
n
t
s
 
c
o
l
o
n
i
z
e
d
 
(
%
)
0 0.5 1 1.5 2 2.5 3
0
5
10
15
20
25
30
35
Number of colonized patients admitted per day 
(oﬀ AB/on AB ratio = 2/3)
(b)
P
a
t
i
e
n
t
s
 
c
o
l
o
n
i
z
e
d
 
(
%
)
12345678
0
10
20
30
Length of stay of colonized patients (weeks)
(c)
P
a
t
i
e
n
t
s
 
c
o
l
o
n
i
z
e
d
 
(
%
)
0 2 04 06 08 0 1 0 0
10
15
20
25
30
35
40
Handwashing compliance percentage
(d)
P
a
t
i
e
n
t
s
 
c
o
l
o
n
i
z
e
d
 
(
%
)
5 1 01 52 02 5
11
12
13
14
15
Uncolonized patients on AB that become CDAD+ (%)
(e)
P
a
t
i
e
n
t
s
 
c
o
l
o
n
i
z
e
d
 
(
%
)
3 3.5 4 4.5 5
12
13
14
15
TSR of colonized CDAD+patients on AB (days)
(f)
Figure 2: Sensitivity analyses of the model parameters. Dashed lines: Scenario 1 (use of AB only); Solid lines: Scenario 2 (use of non-anti-
microbial); Vertical line: baseline values; (a) Percentage of CDAD+ patients that stop AB and start non-AB (baseline = 50%, σ = 0.5); (b)
Number of colonized patients admitted per day in the ratio λoﬀ
C−/λon
C− = 2/3 (baseline λoﬀ
C− = 0.33, λon
C− = 0.5); (c) Length of stay of colonized
patients in weeks (baseline = 4w e e k s ,= γoﬀ
C−/γon
C−= 1/28); (d) Hand-washing compliance percentage (baseline = 60%, η = 0.6); (e) Percentage
of uncolonized and colonized patients on AB (held equal) that become CDAD+ (baseline = 15%, ωon
U− = ωon
C− = −log (0.9893)); (f) Time
to symptoms resolution (TSR) of colonized CDAD+ patients on AB in days (baseline = 3.7 days, δon
C+ = −log (0.73)); AB = antibiotic;
CDAD = clostridium diﬃcile-associated disease; non-AB = nonantibiotic; λoﬀ
C− = CDAD−, colonized, oﬀ antibiotic: admission rate; γon
C− =
CDAD−, colonized, on antibiotic: average length of stay; ωon
U− = CDAD−, uncolonized, on antibiotic: transit to CDAD+; ωon
C− = CDAD−,
colonized, on antibiotic: transit to CDAD+; γoﬀ
C− = CDAD−, colonized, oﬀ antibiotic: average length of stay; λon
C− = CDAD−, colonized, on
antibiotic: admission rate.
5. Discussion
The association between antibiotic use in hospitals and the
colonization of patients with antibiotic-resistant bacteria
such as VRE is well documented [24]. This ﬁnding has
spurredresearchintononantibioticoptionsforthetreatment
of nosocomial infections such as CDAD. For example, the
anionic polymer tolevamer (Genzyme, Inc.) was developed6 Computational and Mathematical Methods in Medicine
Table 2: Distribution of patients and health care workers with or without VRE colonization on the basis of antibiotic versus nonantibiotic
treatment of CDAD.
Patient colonization/HCW
contamination status AB status Model with AB
only
Model with
AB and
non-AB
Change with
non-AB
Diﬀerence
with non-AB
Patient Steady State Values
uncolonized CDAD− patient oﬀ 195.176 202.555 increases 7.390
uncolonized CDAD− patient on 140.383 143.553 increases 3.170
colonized CDAD− patient oﬀ 10.7197 9.0598 decreases −1.6599
colonized CDAD− patient on 47.3343 38.4389 decreases −8.8954
uncolonized CDAD+ patient on 4.7467 2.4307 decreases −2.3160
colonized CDAD+ patient on 1.6721 0.6798 decreases −0.9923
uncolonized CDAD+ patient oﬀ 0.0 2.4535 increases 2.4535
colonized CDAD+ patient oﬀ 0.0 0.6570 increases 0.6570
Patient Totals at Steady State
total patients 400.03 399.828
Total VRE-colonized patients 59.7361 48.83555 decreases −10.8905
total CDAD+ patients 6.4188 6.2210 decreases −0.1978
total CDAD+ patients on AB 6.4188 3.1105 decreases −3.3083
total patients on AB 194.136 185.102 decreases −9.034
Percentage of Patients Colonized at Steady State
% of all patients colonized 14.930% 12.214% decreases −2.716%
%C D A D − patients colonized 14.749% 12.068% increases −2.681%
% CDAD+ patients colonized 26.050% 21.488% decreases −4.562%
HCW Steady State Values
uncontaminated HCW 95.3347 96.1513 increases 0.8166
contaminated HCW 4.6653 3.8487 decreases −0.8166
CDAD = Clostridium diﬃcile-associated disease; VRE = vancomycin-resistant enterococci; HCW = health care worker; CDAD+ = Clostridium diﬃcile-
associated disease positive; CDAD− = clostridium diﬃcile-associated disease negative; AB = antibiotic.
to neutralize clostridial toxins without adversely aﬀecting the
normal ﬂora of the gut [13, 14]. Results from a phase III trial
revealed that the recurrence rate of CDAD was reduced sig-
niﬁcantly when compared with vancomycin and metronida-
zole; however, the study failed to meet its primary endpoint
due to the high dropout rate associated with tolevamer [25].
As the development of the therapy was subsequently halted,
its impact on the prevalence of VRE is unknown.
More recent publications have reported on the safety
and eﬀectiveness of FDIT for the treatment of CDAD. This
therapy involves the introduction of a stool transplant into
the duodenum or colon via a gastroscope or colonoscope,
respectively, to repopulate the microﬂora of the bowel [15,
16]. Although used for decades, particularly in Scandinavian
countries, the clinical data describing FDIT are limited;
still, available reports suggest that the treatment is safe and
eﬀective even in patients with refractory CDAD [15–17].
A recent review of 16 publications concluded that 91%
of all reported patients with recurrent C. diﬃcile infection
who were treated with FDIT were cured after one or more
infusions [26]. The impact of FDIT on the prevalence of
VRE, however, remains uncertain.
The availability of a nonantibiotic treatment for CDAD
raises interesting questions regarding its possible impact
on the prevalence of VRE compared with conventional
antibiotic therapy. Our study adapted an existing model of
VREprevalencewithinahospitalsettingtostudythepossible
eﬀect of the introduction of a nonantibiotic treatment
for CDAD. The study found that treatment of 50% of
patients with CDAD with a nonantibiotic regimen resulted
in an approximately 2.75% absolute reduction (18% relative
reduction) in VRE-colonized patients compared with a
scenario, whereby all CDAD patients received antibiotics.
This reduction in VRE prevalence represents a meaning-
ful impact within a hospital, given the costs associated with
the management of VRE-colonized patients and potential
clinical impact of VRE infections. For a 400-bed hospital, the
analysis estimated a reduction of 275 cases of VRE coloniza-
tion. On the basis of an average cost of contact precautions
of USD $2,694.01 (CDN $3,191.83 at exchange of 0.844034),
this would result in cost savings of approximately USD
$740,800 a year [27] .As m a l lr e d u c t i o ni nV R Ep r e v a l e n c e
may also have a substantial impact on the clinical outcome
andcostsofVREinfections.VREinfectionhasbeenobserved
tooccurinasmanyas11.1%ofVRE-colonizedpatients[12].
The cost to treat a patient with a VRE infection has been
reported as approximately USD $13,000 [28]. The mortality
rate for a VRE infection has been estimated as 39% to 49%
[29]. On the basis of the current model, an 18% reduction
in VRE prevalence could avert as many as 30.5 cases of VREComputational and Mathematical Methods in Medicine 7
infectionfora400-bedhospital.ThisreductioninVREinfec-
tions could lead to a cost savings of USD $396,500 per year
and could prevent up to 15 VRE-associated deaths annually.
Note that the current study excludes other types of
antibiotic-resistant bacteria such as methicillin-resistant
Staphylococcus aureus, which would also be aﬀected by
reduced use of antibiotics within a hospital. As such, it is
likely that the study underestimates the extent of the impact
of a nonantibiotic treatment for CDAD.
The study shares limitations that are common to all
mathematical models in that it requires the use of data from
multiple sources to model processes that have not been fully
observed. The validity of such a model comes from the use
of realistic assumptions and clinical review. In this case, the
study was derived from a published model that was based on
patterns of VRE transmission that have been widely studied
and baseline parameters that were obtained from actual
hospital data [19]. Given the variability that may exist for
some of the model parameters, extensive sensitivity analyses
were conducted. These sensitivity analyses revealed that the
following variables had the most inﬂuence on the prevalence
of VRE: the rate of antibiotic initiation or discontinuation in
CDAD negative and positive patients, the length of stay of
VRE-colonized patients, hand-washing compliance, and the
number of VRE-colonized patients admitted per day. All of
these variables would be expected to diﬀer among hospitals
given local infection control policies and the endemic rates
of VRE colonization in the community.
6. Conclusions
Use of a nonantibiotic treatment in hospital patients with
CDAD may signiﬁcantly reduce the colonization of patients
with VRE and the associated burden of disease.
Appendix
The CDAD epidemic within the hospital setting is described
mathematically by a system of nonlinear ordinary diﬀer-
ential equations. The populations under consideration are
as follows: uncolonized CDAD− patients oﬀ antibiotics
(Poﬀ
U−), uncolonized CDAD− patients on antibiotics (Pon
U−),
colonized CDAD− patients oﬀ antibiotics (Poﬀ
C−), colonized
CDAD− patients on antibiotics (Pon
C−), uncolonized CDAD+
patients oﬀ antibiotics (Poﬀ
U+), uncolonized CDAD+ patients
on antibiotics (Pon
U+), colonized CDAD+ patients oﬀ antibi-
otics (Poﬀ
C+), colonized CDAD+ patients on antibiotics (Pon
C+),
uncontaminated health care workers (HU), and contam-
inated health care workers (HC). Each population is a
function of time (t) in days, and each population has initial
conditions prescribed at time 0. The rates of change of these
populations are governed by
dPoﬀ
U−
dt
= λoﬀ
U− −τstart
U− Poﬀ
U− +τ
stop
U− Pon
U− −γoﬀ
U−Poﬀ
U− +δoﬀ
U+Poﬀ
U+,
dPon
U−
dt
= λon
U− −τ
stop
U− Pon
U− +τstart
U− Poﬀ
U− −ωon
U−Pon
U−
−αon
U−βon
U−

1 −η
HC
Nh
Pon
U− +δon
U+Pon
U+ −γon
U−Pon
U−,
dPoﬀ
U+
dt
= σωon
U−Pon
U− −δoﬀ
U+Poﬀ
U+,
dPon
U+
dt
= (1 −σ)ωon
U−Pon
U− −δon
U+Pon
U+
− αon
U+βon
U+

1 −η
HC
Nh
Pon
U+,
dPoﬀ
C+
dt
= σωon
C−Pon
C− −δoﬀ
C+Poﬀ
C+,
dPon
C+
dt
= (1 −σ)ωon
C−Pon
C− −δon
C+Pon
C+
+αon
U+βon
U+

1 −η
HC
Nh
Pon
U+,
dPoﬀ
C−
dt
= λoﬀ
C− −τstart
C− Poﬀ
C− +τ
stop
C− Pon
C−
− γoﬀ
C−Poﬀ
C− +δoﬀ
C+Poﬀ
C+,
dPon
C−
dt
= λon
C− −τ
stop
C− Pon
C− +τstart
C− Poﬀ
C− −ωon
C−Pon
C−
+αon
U−βon
U−

1 −η
HC
Nh
Pon
U− +δon
C+Pon
C+ −γon
C−Pon
C−,
dHU
dt
=−

αC−κoﬀ
−

Poﬀ
C−
Np

+αC−κon
−

Pon
C−
Np

+αC+κon
+

Pon
C+
Np

+αC+κoﬀ
+

Poﬀ
C+
Np

× ρHU +μHC,
dHC
dt
=

αC−κoﬀ
−

Poﬀ
C−
Np

+αC−κon
−

Pon
C−
Np

+αC+κon
+

Pon
C+
Np

+αC+κoﬀ
+

Poﬀ
C+
Np

× ρHU − μHC.
(A.1)
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